Anti-VEGF agents have now been in ophthalmic use for the past 10 years [17], and the wealth of data from clinical and real-world studies support the clear, positive benefit–risk balance associated with their use for treatment of retinal disorders [50, 51]. This evidence concerns the gene VEGFA and retinal disorder.